The Gore SCAFFOLD Clinical Study

NCT ID: NCT01901874

Last Updated: 2020-10-29

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

312 participants

Study Classification

INTERVENTIONAL

Study Start Date

2013-07-31

Study Completion Date

2020-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Evaluate the safety and efficacy of the GORE® Carotid Stent for the treatment of carotid artery stenosis in patients at increased risk for adverse events from carotid endarterectomy

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a prospective, multicenter, single-arm clinical study comparing outcomes with the GORE® Carotid Stent to a performance goal derived from carotid endarterectomy outcomes in high-surgical-risk patients.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Carotid Artery Disease Carotid Artery Stenosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Carotid Artery Stenting

Carotid Artery Stenting with the GORE® Carotid Stent

Group Type EXPERIMENTAL

Carotid Artery Stenting

Intervention Type DEVICE

Carotid Artery Stenting with the GORE® Carotid Stent

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Carotid Artery Stenting

Carotid Artery Stenting with the GORE® Carotid Stent

Intervention Type DEVICE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

GORE® Carotid Stent

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patient is at least 18 years old at informed consent
* Patient is willing and capable of complying with all study protocol requirements, including specified follow-up period and can be contacted by telephone.
* Patient is willing to provide written informed consent prior to enrollment in study.
* Patient is either:

* Symptomatic with carotid stenosis ≥50% as determined by angiography using NASCET methodology. Symptomatic is defined as amaurosis fugax ipsilateral to the carotid lesion; Transient Ischemic Attack (TIA) or non-disabling stroke within 180 days of the procedure within the hemisphere supplied by the target vessel; OR
* Asymptomatic with carotid stenosis ≥80% as determined by angiography using NASCET methodology
* Patient must be considered high risk for adverse events during carotid endarterectomy

Exclusion Criteria

* Patient has life expectancy of less than one year.
* Patient is experiencing (or has experienced) an evolving, acute, or recent disabling stroke.
* Patient has anticipated or potential sources of emboli (e.g. atrial fibrillation, known previously symptomatic patent foramen ovale (PFO), mechanical heart valve, or Deep Vein Thrombosis (DVT) treated within 6 months).
* Patient has had an acute myocardial infarction within 72 hours prior to the index procedure.
* Patient has a history of major, disabling ipsilateral stroke with residual deficit that may confound the neurological subject assessments.
* Patient has known severe carotid stenosis contralateral to the target lesion requiring treatment within 30 days following the index procedure.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

W.L.Gore & Associates

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

William Gray, MD

Role: PRINCIPAL_INVESTIGATOR

Lankenau Heart Institute

Peter Schneider, MD

Role: PRINCIPAL_INVESTIGATOR

Kaiser Health System, Honolulu

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Kaiser Permanente Hawaii

Honolulu, Hawaii, United States

Site Status

Lankenau Heart Institute

Wynnewood, Pennsylvania, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

References

Explore related publications, articles, or registry entries linked to this study.

Gray WA, Levy E, Bacharach JM, Metzger DC, Randall B, Siddiqui A, Schonholz C, Alani F, Schneider PA. Evaluation of a novel mesh-covered stent for treatment of carotid stenosis in patients at high risk for endarterectomy: 1-year results of the SCAFFOLD trial. Catheter Cardiovasc Interv. 2020 Jul;96(1):121-127. doi: 10.1002/ccd.28586. Epub 2019 Nov 11.

Reference Type DERIVED
PMID: 31713310 (View on PubMed)

Provided Documents

Download supplemental materials such as informed consent forms, study protocols, or participant manuals.

Document Type: Study Protocol

View Document

Document Type: Statistical Analysis Plan

View Document

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

GCS 10-08

Identifier Type: -

Identifier Source: org_study_id